Thermo Fisher Scientific (TMO) Tops Q4 EPS by 13c, Beats on Revenues
Thermo Fisher Scientific (NYSE: TMO) reported Q4 EPS of $2.79, $0.13 better than the analyst estimate of $2.66. Revenue for the quarter came in at $6.05 billion versus the consensus estimate of $5.7 billion.
Fourth Quarter and Full Year 2017 Highlights
- Fourth quarter revenue grew 22% to $6.05 billion.
- Full year revenue grew 14% to $20.92 billion.
- Fourth quarter GAAP diluted earnings per share (EPS) decreased 18% to $1.30.Full year GAAP diluted EPS increased 10% to $5.59. GAAP results include a one-time tax provision of $204 million associated with the recent enactment of tax reform legislation in the U.S.
- Fourth quarter adjusted EPS increased 16% to $2.79.Full year adjusted EPS increased 15% to $9.49.
- Invested $0.9 billion in R&D during the year and launched high-impact products across all segments, highlighted by the Thermo Scientific Q-Exactive HF-X mass spectrometer, Thermo Scientific Krios G3i cryo transmission electron microscope, Applied Biosystems SeqStudio genetic analyzer and the Oncomine Dx Target Test.
- Delivered strong year-over-year growth in Asia-Pacific and Emerging Markets, led by outstanding performance in China, and added new capabilities to support growth opportunities in China, South Korea and the Middle East.
- Deployed $7.8 billion in 2017 on strategic acquisitions, adding leading biopharma contract development and manufacturing services through Patheon and expanding our offerings in bioproduction, cloud-based informatics, electron microscopy and transplant diagnostics.
- Returned $1 billion of capital to shareholders in 2017 through stock buybacks and dividends.
For earnings history and earnings-related data on Thermo Fisher Scientific (TMO) click here.